1177:HKEXSino Biopharmaceutical Limited Analysis

Sino Biopharmaceutical (1177.HK) is trading at HKD 4.98, well below its 20‑day SMA of 4.76 and 50‑day SMA of 4.93, indicating short‑term price weakness. Despite the bearish price trend, the MACD histogram is positive (0.067) and the MACD line sits above the signal line, delivering a bullish technical signal. Momentum is neutral, with a 14‑day RSI of 52.7, suggesting neither overbought nor oversold conditions. The stock’s volatility over the past 30 days is high at ≈47 %, and the beta of 0.5 points to modest market sensitivity. Fundamentally, revenue grew 9.8 % YoY and innovative product sales jumped 27.2 %, driving a 140 % surge in attributable profit. The company generates strong cash flow, posting HKD 9.29 bn operating cash flow and HKD 6.60 bn free cash flow, while maintaining a cash pile of HKD 22.96 bn.
Valuation metrics show a PE of 33.2× versus the industry average of 29.1×, yet the discounted‑cash‑flow model assigns a fair value of HKD 7.72, implying upside of roughly 72 %. The dividend yield of 1.9 % is supported by a payout ratio of 63 %, indicating sustainable income for shareholders. Debt remains elevated at HKD 16.07 bn, giving a debt‑to‑equity of 38.2 %, but the robust cash position and healthy operating margins (gross 82 %, operating 20 %) provide ample coverage. The bearish technical backdrop is partially offset by the bullish MACD and the sizable valuation gap, creating a potential entry point for risk‑aware investors. With a target median price of HKD 8.68 from analysts (20 consensus) and a strong “strong‑buy” consensus, the medium‑ to long‑term upside appears compelling. Investors should monitor execution of the R&D pipeline and any regulatory developments in China, as these will shape future earnings momentum.